People | April 29, 2026
NADMED Limited appoints James Lee as CEO to drive global expansion
Former Novo Nordisk and Pharmanovia executive to lead next growth phase in NAD diagnostics and personalised health innovation
Former Novo Nordisk and Pharmanovia executive to lead next growth phase in NAD diagnostics and personalised health innovation
The company receives approval for blood-based test enabling objective differentiation of schizophrenia and bipolar disorder
With big pharma leaning on external pipelines, the company sees opportunity in de-risked, high-impact assets with clear clinical endpoints
His appointment is expected to strengthen scientific input in policy discussions across public health, biotech, and translational research
At IIT Roorkee’s Vision 2047 conference, the union minister highlights BioE3 policy, rising biotech startups, and major scientific milestones
The collaboration underscores a broader industry shift toward hybrid research models that integrate computational biology with advanced experimental systems
By cutting pain crises & boosting haemoglobin
Together, the companies aim to deliver an integrated toolkit for biomarker discovery and clinical research
The company announced that its Phase III FENhance 1 and 2 studies both met their primary endpoints
The Phase III METEOROID study met its primary endpoint, with ENSPRYNG cutting the risk of a first relapse by 68% compared to placebo in adults and adolescents
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
